Rutsis & Associates has a group of contract distributors around the U.S. that sell a Genetic Cancer Screening Test for GeneID, a CLIA Testing Laboratory. We test 31 genes for mutations that will indicate the likelihood of the occurrence of various cancers.

Consult and look for market opportunities world-wide for this streaming cardiac monitoring technology that is monitored live 24/7.

Personalized Medicine, Genetic Testing and BioInformatics

Chelexa BioSciences commercializes and licenses innovative genetically engineered technology to help in the control of infections.

Chelexa BioSciences, Inc. technology targets PREVENTION of biofilm (bacterial colonization) formation and biofilm related infections. Once formed, biofilms are virtually untreatable with annual treatment costs rising into the billions of dollars. Hospital Acquired Infections along with Diabetic Ulcers/Pressure Ulcers cost US healthcare payers over $65 billion in annual treatment costs. Biofilms are 1000 times more resistant to antibiotics than planktonic (single) bacteria. 60% of medical device implant infections are biofilm related, while 80% plus of human infectious diseases are biofilm related. Staph aureus and Staph epidermidis are the most widely isolated bacteria found to cause biofilm formation and biofilm related infections. Our technology targets PREVENTION of bacterial-to-substrate adherence at the cellular level, thus preventing biofilm formation and biofilm related infections. Biofilm formation and biofilm related infections may be associated with acute and chronic wounds (such as Diabetic and Pressure Ulcers), along with implanted medical devices such as in-dwelling catheters, IUDs, breast implants, contact lenses, pacemakers, ICDs, orthopedic devices and sutures as examples. Laboratory studies have shown that planktonic bacteria typically: attach within minutes, form strongly attached microcolonies within 2-4 hours, develop extracellular polymeric substance (EPS) and become increasingly tolerant to antibiotics and evolve into fully mature biofilm colonies within 6-12 hours, shed planktonic bacteria within 2-4 days and rapdily recover from mechanical disruption and reform mature biofilms within 24 hours.

SkinVent Pharmaceuticals is commercializing a family of topical OTC and Rx products to be used for the routine care of traumatized skin and prevention of staph-induced flare-ups in eczema.

Medical Industry Consulting in devices, biopharmaceuticals and physician benefits packages.

Managed Miami Medtronic District for the Cardiac Rhythm Management Division ( implantable cardiac pacemakers & defibrillators) to include sales and clinical specialists.

Managed sales and clinical activities for the southeast and southwest U.S. as well as the northern Carribean. Responsibilities also included sales and physician training programs.